Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

FDA Approves Epysqli as Second Soliris Biosimilar

July 22nd 2024

By Skylar Jeremias

Article

The FDA approves Samsung Bioepis’ Epysqli (eculizumab-aagh), marking the second US approval for a biosimilar referencing Soliris (eculizumab).

Biosimilars in America: Overcoming Barriers and Maximizing Impact

July 21st 2024

By Skylar Jeremias

Podcast

Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.

Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction

July 20th 2024

By Deana Ferreri, PhD

Article

Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.

The Top 5 Biosimilar Articles for the Week of July 15

July 19th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of July 15, 2024.

Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch

July 18th 2024

By Lana Pine

Article

Health literacy was categorized as problematic in 36.2% of patients and insufficient in 15.1%.

Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development

July 17th 2024

By Skylar Jeremias

Article

The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.

Biosimilar DMARDs Offer Cost-Effective Option for Patients With RA After Failed Methotrexate Treatment

July 15th 2024

By Cameron Santoro

Article

Economic evaluations of biosimilar disease-modifying antirheumatic drugs (DMARDs) suggest cost-effectiveness for patients with rheumatoid arthritis (RA) who did not respond well to methotrexate, potentially improving patient outcomes and health care affordability.

BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed

July 15th 2024

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.

IPD Analytics' Jeffrey Casberg Discusses Recent Biosimilar Approvals

July 14th 2024

By Cameron Santoro

Video

Jeffrey Casberg, MS, RPh, senior vice president of pharmacy at IPD Analytics, highlights new FDA approvals, the launch of the first tocilizumab biosimilar, and how pharmacy and therapeutics committees approach new pipeline drugs.

PBMs Drive Up Drug Costs, Squeeze Out Generics and Biosimilars, FTC Report Finds

July 12th 2024

By Mary Caffrey

Article

A long-awaited report from the Federal Trade Commission (FTC) finds that vertical integration and consolidation have worked against consumers and independent pharmacies.